C4 Therapeutics
CCCCC4 Therapeutics is a clinical-stage biopharmaceutical company focused on the development of targeted protein degradation (TPD) therapies.
$474.33M+236%
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Revenue estimate$8.2M
EPS estimate-$0.23
Competitors
By market cap
By revenue growth
Profile
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on the development of targeted protein degradation (TPD) therapies. Using its proprietary TORPEDO platform, the company designs small-molecule degraders that utilize the body's natural protein disposal system to treat cancer, inflammation, and neurodegenerative diseases.
Competitive position
A clinical-stage innovator in the targeted protein degradation space with a proprietary platform for both molecular glues and bifunctional degraders.
GeographiesUnited States, China
Customer segmentsPharmaceutical companies, Patients
Business modelR&D, Licensing, Drug Development
SuppliersContract research organizations, Raw material suppliers, Laboratory equipment providers
CustomersBiopharmaceutical partners, Clinical trial sites, Specialty pharmacies
CountryUnited States of America
Listed2020
Employees145.0
CEOAndrew J. Hirsch
SectorHealthcare
IndustryBiotechnology
Websitec4therapeutics.com
FilingsSEC EDGAR
Questions, answered.
- What is C4 Therapeutics's market cap?
- C4 Therapeutics (CCCC) has a market capitalization of $474.3M and trades on NASDAQ.
- Who are C4 Therapeutics's competitors?
- C4 Therapeutics's key competitors include Kymera Therapeutics, Arvinas, Nurix Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does C4 Therapeutics partner with?
- C4 Therapeutics's notable partners include Betta Pharmaceuticals, Merck KGaA, Roche, and others.
- Where is C4 Therapeutics headquartered?
- C4 Therapeutics is headquartered in United States of America and employs approximately 145 people. It has been publicly traded since 2020.